The short version of research compound fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-30. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
=== Influences === β-TG levels may increase with age. It is elevated in diabetes mellitus. β-TG levels have been found to be increased by treatment with the synthetic estrogen ethinylestradiol, though were not significantly increased by the natural estrogen estradiol valerate. Levels of β-TG have also been found to be increased or unchanged during normal pregnancy.
Portal 2 was released as a standalone game in April 2011 on both computers and consoles. It is considered one of the greatest video games of all time by numerous publications and critics. It received acclaim for its gameplay, pacing, dark humor, writing, the voice work of McLain, Merchant, and Simmons, and its challenging but surmountable learning curve.
Following the discontinuation of Lente insulin for human use, the FDA approved a veterinary formulation derived from porcine insulin, known as Vetsulin, for daily administration in dogs and twice-daily use in cats. Insulin analogs developed for human use after Lente insulin's discontinuation have not yet been demonstrated to offer the same benefits and predictability in feline and canine patients. For this reason, along with other considerations, Lente insulin remains a widely used treatment for diabetes in both dogs and cats. Lente insulin is currently produced by Merck Animal Health under the name Vetsulin.
The major part of the PAP is the nèiwèi bùduì (Chinese: 内卫部队); translations include "internal security forces", "internal security troops", and "internal guards corps". Internal security forces are divided into provincial-level formations with geographical areas of responsibility. They are subordinated to PAP headquarters; the 2017-2018 reforms removed control of PAP units from local government. Internal security forces are focused on domestic security missions, maintaining stability in western China, guarding government compounds, disaster relief, and responding to major anti-government unrest. The zǒngduì (Chinese: 总队) is the provincial formation. They are called "corps" by the PAP; Western analysts have used "contingent", "general corps", and "detachment". Most are corps deputy leader grade formations. The exceptions are the Beijing and Xinjiang corps which are corps leader grade; their subordinate entities, except for the logistics and equipment bureaus, are one grade higher than in the other corps. Hong Kong and Macau do not have corps. Corps have mobile detachments and duty detachments (Chinese: 执勤支队; pinyin: zhíqín zhīduì). Duty detachments protect government compounds and perform routine duties; they may exist because the CCP lacks confidence in the ability of local public security forces to handle "mass incidents". Mobile detachments (Chinese: 机动支队; pinyin: jīdòng zhīduì) are rapid reaction units roughly corresponding to PLAGF regiments. Some were existing corps mobile units before the reforms. Most were transferred from the disbanded mobile divisions.
Sources: en.wikipedia.org
Based on evidence from the geologic record, life most likely emerged on Earth between 4.32 and 3.48 Gya. In 2017, the earliest physical evidence of life was reported to consist of microbialites in the Nuvvuagittuq Greenstone Belt of Northern Quebec, in banded iron formation rocks at least 3.77 and possibly as old as 4.32 Gya. The micro-organisms could have lived within hydrothermal vent precipitates, soon after the 4.4 Gya formation of oceans during the Hadean. The microbes resemble modern hydrothermal vent bacteria, supporting the view that abiogenesis began in such an environment. Later research disputed this interpretation of the data, stating that the observations may be better explained by abiotic processes in silica-rich waters, "chemical gardens," circulating hydrothermal fluids, or volcanic ejecta. Biogenic graphite has been found in 3.7 Gya metasedimentary rocks from southwestern Greenland and in microbial mat fossils from 3.49 Gya cherts in the Pilbara region of Western Australia. Evidence of early life in rocks from Akilia Island, near the Isua supracrustal belt in southwestern Greenland, dating to 3.7 Gya, have shown biogenic carbon isotopes. In other parts of the Isua supracrustal belt, graphite inclusions trapped within garnet crystals are connected to the other elements of life: oxygen, nitrogen, and possibly phosphorus in the form of phosphate, providing further evidence for life 3.7 Gya.
== Clinical significance == Deletions and mutations in this gene are associated with supravalvular aortic stenosis (SVAS) and the autosomal dominant cutis laxa. Other associated defects in elastin include Marfan syndrome, emphysema caused by α1-antitrypsin deficiency, atherosclerosis, Buschke–Ollendorff syndrome, Menkes syndrome, pseudoxanthoma elasticum, and Williams syndrome.
=== Works cited === Brand, Chad; Mitchell, Eric (2015). Holman Illustrated Bible Dictionary. B&H Publishing Group. ISBN 978-0-8054-9935-3. Cross, Frank Moore (1973). Canaanite Myth and Hebrew Epic. Cambridge, Massachusetts: Harvard University Press. ISBN 978-0-674-09176-4. LCCN 72076564. OCLC 185400934. Dever, William (2003). Who Were the Early Israelites and Where Did They Come From?. Eerdmans. ISBN 978-0-8028-0975-9. Archived from the original on 1 July 2023. Retrieved 14 August 2015. Dever, William G. (2005). Did God Have a Wife?: Archaeology and Folk Religion in Ancient Israel. Wm. B. Eerdmans. ISBN 978-0-8028-2852-1. Retrieved 7 February 2016. Faust, Avraham (2015). "The Emergence of Iron Age Israel: On Origins and Habitus". In Levy, Thomas E.; Schneider, Thomas; Propp, William H. C. (eds.). Israel's Exodus in Transdisciplinary Perspective: Text, Archaeology, Culture, and Geoscience. Springer. pp. 467–482. ISBN 978-3-319-04768-3. Archived from the original on 21 October 2021. Retrieved 31 March 2023. Goldenberg, David M. (11 April 2009). The Curse of Ham: Race and Slavery in Early Judaism, Christianity, and Islam. Princeton University Press. pp. 90–91. ISBN 978-1-4008-2854-8. OCLC 1162398032. Grabbe, Lester L. (2004). A History of the Jews and Judaism in the Second Temple Period. T&T Clark International. ISBN 978-0-567-04352-8. Archived from the original on 1 July 2023. Retrieved 14 August 2015. Grabbe, Lester L., ed. (2008). Israel in Transition: From Late Bronze II to Iron IIa (c. 1250–850 B.C.E.). T&T Clark International. ISBN 978-0-567-02726-9.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.